Skip to content

Study to Investigate Pregnancy Outcomes in Female Participants Exposed to Subcutaneous (SC) Peginterferon Beta-1a and Intramuscular (IM) Interferon Beta-1a Reported in a German Participant Support Program

Non-interventional Safety Study to Investigate Pregnancy Outcomes in Female Patients Exposed to SC Peginterferon Beta-1a and IM Interferon Beta-1a Reported in a German Patient Support Program

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04655222
Enrollment
470
Registered
2020-12-07
Start date
2021-04-30
Completion date
2021-10-15
Last updated
2023-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting

Brief summary

The primary objective(s) of the study is to evaluate the impact of exposure to SC Peginterferon beta-1a or IM Interferon beta-1a before and during pregnancy on pregnancy outcome in female participants who had registered in the German Patient Support Program (PSP) and of whom a pregnancy report and pregnancy outcome report is available. The secondary objectives of this study are applicable for a subpopulation of the above-mentioned population, i.e. for participants of whom data on a standardized questionnaire collected during a telephone interview is available.

Detailed description

This is an observational study with focus on existing pregnancy reporting forms (retrospective part) and a patient's questionnaire which is completed at a single point of time (prospective part). Main data source for the retrospective data (from 2014 until December 2019) will be captured from multiple sclerosis service-center (MSSC) database, i.e. the entered pregnancy report (to be completed as soon as pregnancy becomes known) and pregnancy outcomes report (to be completed after completion of pregnancy). Prospective data (December 2020 to 31 March 2021) will be captured as standardized ePDF questionnaire completed during telephone interview. If the pregnancy report or the pregnancy outcome report is incomplete, i.e. the data above was not collected, the open questions will be addressed during a telephone interview performed by the MSSC and the new information will be entered into the MSCC database. The patient questionnaire will be completed at a single point of time during the telephone interview performed by the MSSC.

Interventions

DRUGInterferon Beta Therapy

Administered as specified in the treatment arm.

Sponsors

Biogen
Lead SponsorINDUSTRY

Study design

Observational model
CASE_ONLY
Time perspective
OTHER

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Diagnosed relapsing-remitting multiple sclerosis (RRMS) or clinically isolated syndrome (CIS) (CIS indication only applicable for interferon beta-1a) * Exposure to either SC Peginterferon beta-1a therapy or an IM Interferon beta-1a therapy before or during pregnancy * Registered in the PSP of the multiple sclerosis service- center (MSSC) and agreed in writing to the privacy policy of the registration form * Reported pregnancy data (pregnancy report and pregnancy outcome report) available at MSSC. Note: only pregnancy data (i.e. obtained until 15 October 2020) will be considered. * Pregnancy outcome in the retrospectively collected data was a live birth

Exclusion criteria

Any criteria that does not fulfil the above-mentioned inclusion criteria. NOTE: Other protocol defined Inclusion criteria may apply

Design outcomes

Primary

MeasureTime frameDescription
Percentage of Participants With Live Births Without Congenital Anomaliesup to end of study (4 months)
Percentage of Participants With Live Births With Congenital Anomaliesup to end of study (4 months)
Percentage of Participants With Ectopic Pregnancies8 weeks of gestation
Percentage of Participants With Spontaneous Abortionsup to 22 weeks of gestationA spontaneous abortion is defined as fetal death before 22 weeks of gestation.
Percentage of Participants With Elective Abortionsup to Week 20 of gestation
Percentage of Participants With Preterm Birthsup to 37 weeks of gestationA preterm birth is a birth before 37 completed weeks of gestation.
Percentage of Participants With Stillbirthsfrom 22 week up to 39 weeks of gestationA still birth is defined as fetal death at \>22 weeks gestation.

Secondary

MeasureTime frameDescription
Time to Start Subcutaneous Peginterferon Beta-1a or Intramuscular Interferon Beta-1a Therapy in Relation to Beginning of Pregnancyup to 39 weeks of gestation
Percentage of Women Restarting Subcutaneous Peginterferon Beta-1a or Intramuscular Interferon Beta-1a Therapy After Birthup to end of study (4 months)
Time to Restart Subcutaneous Peginterferon Beta-1a or Intramuscular Interferon Beta-1a Therapy in Relation to Birthup to end of study (4 months)
Percentage of Women Starting Another Multiple Sclerosis (MS) Therapy During/After Pregnancyup to end of study (4 months)
Time to Start Another MS Therapy During/After Pregnancy in Relation to Birthup to end of study (4 months)
Average Weight of the ChildrenFrom Birth up to Month 48
Percentage of Multiple Sclerosis Relapses in Women with Subcutaneous Peginterferon Beta-1a or Intramuscular Interferon Beta-1a Therapy Before, During and After Pregnancyup to end of study (4 months)
Change From Baseline Expanded Disability Status Scale (EDSS) During and After Pregnancy to Expanded Disability Status Scale (EDSS) Before PregnancyWeek 0 up to Week 39 of gestationEDSS is based on a standardized neurological exam and focuses on symptoms that commonly occur in multiple sclerosis (MS). Scores range from 0.0 (normal) to 10.0 (death due to MS).
Number of Women Breastfeeding Under Subcutaneous Peginterferon Beta-1a or Intramuscular Interferon Beta-1a Therapyup to end of study (4 months)
Duration of Subcutaneous Peginterferon Beta-1a or Intramuscular Interferon Beta-1a Therapy Exposed Breastfeedingup to end of study (4 months)
Time to First Multiple Sclerosis (MS) Relapse After Introduction of the First Supplemental Feedings in Women With Subcutaneous Peginterferon Beta-1a or Intramuscular Interferon Beta-1a Therapy During Lactationup to end of study (4 months)
Percentage of Women Using Other Therapies During Pregnancyup to 39 weeks of gestation
Average Length of the ChildrenFrom Birth up to Month 48
Average Head Circumference of the ChildrenFrom Birth up to Month 48
Percentage of Abnormalities Diagnosed During Pediatric Check-upsup to Month 48
Percentage of Women Discontinued Subcutaneous Peginterferon Beta-1a or Intramuscular Interferon Beta-1a Therapy During Pregnancyup to 39 weeks of gestation
Time to Discontinuation of Subcutaneous Peginterferon Beta-1a or Intramuscular Interferon Beta-1a Therapy in Relation to Beginning of Pregnancyup to 39 weeks of gestation
Percentage of Women Starting Subcutaneous Peginterferon Beta-1a or Intramuscular Interferon Beta-1a Therapy During Pregnancyup to 39 weeks of gestation

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 9, 2026